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Abstract 
RhoA and RhoC contribute to the regulation of glutamine metabolism, which is a 
crucial determinant of cell growth in some types of cancer. Here we investigated the 
participation of RhoA and RhoC in the response of prostate cancer cells to glutamine 
deprivation. We found that RhoA and RhoC activities were up- or downregulated by 
glutamine reduction in PC3 and LNCaP cells, which was concomitant to a reduction in 
cell number and proliferation. Stable overexpression of wild type RhoA or RhoC did 
not alter the sensitivity to glutamine deprivation. However, PC3 cells expressing 
dominant negative RhoA
N19
 or RhoC
N19
 mutants were more resistant to glutamine 
deprivation. Our results indicate that RhoA and RhoC activities could affect cancer 
treatments targeting the glutamine pathway. 
Introduction 
In cancer cells, a substantial amount of energy is produced by aerobic glycolysis 
and most of the incoming glucose is converted to lactate (Warburg effect) 
1
. The lower 
rates of ATP generated by aerobic glycolysis are partially compensated by 
glutaminolysis. In this process, glutamine is converted to glutamate by glutaminase and 
further metabolized to α-ketoglutarate, which feeds into the tricarboxylic acid (TCA) 
cycle 
2
. Glutamine also participates in the prevention of oxidative damage, and in the 
biosynthesis of nonessential amino acids, nucleotide and fatty acids 
3
. Therefore, many 
tumor cells rely on glutamine to maximize their growth 
4
 and targeting the glutamine 
pathway is considered a promising strategy for treating cancer.  
RhoA and RhoC are highly homologous GTPases (approximately 92% amino 
acid identity) that have each been implicated in glutamine metabolism 
5-7
. RhoA has 
been better characterized than RhoC, however several studies have demonstrated that 
they present distinct functions in cancer. RhoA is frequently involved in cell cycle 
progression and migration, whereas RhoC is linked to metastasis and reduced cell 
survival 
8, 9
. 
RhoA inhibition in an epithelial mammalian cell model was synthetic lethal with 
Myc, a master regulator of glutamine metabolism 
7
. Inhibition of RhoA induced 
apoptosis in Myc-transformed cells, which was reversed by exogenous α-ketoglutarate 
treatment. In addition, Myc was unable to elevate glutamate levels when the Rho 
subfamily was inhibited with C3 transferase Rho inhibitor, suggesting that Myc is 
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dependent on the signaling mediated by Rho to supply the glutamine demands of 
transformation 
7
. In NIH3T3 cells, the pharmacological inhibition of a specific splice 
variant of mitochondrial glutaminase (GLS1) was capable of reversing the 
transformation caused by the RhoGEF Dbl oncogenic protein 
5
. Dbl has been shown to 
activate several Rho GTPases, including RhoA 
10
. The colony forming ability of 
NIH3T3 cells transformed by overexpression of RhoC, Rac1 or Cdc42 was also blocked 
by GLS1 knockdown, indicating that inactivation of glutaminolysis was sufficient to 
prevent Rho GTPase-induced transformation 
5
. Silencing of RhoC in inflammatory 
breast cancer cells markedly decreased glutamine uptake, without altering glucose 
uptake or lactate production. Regardless of the lower glutamine uptake, the cells 
remained dependent on glutamine. RhoC knockdown also increased glutamine 
synthetase, but did not alter GLS1 
6
.  
Despite these recent studies, the relative contributions of RhoA and RhoC in 
glutamine metabolism remain unclear. Here, we compare the roles of both proteins in 
glutamine dependency of prostate cancer cells by evaluating the effects of RhoA or 
RhoC activation and inactivation on the survival of prostate cancer cell lines cultured 
under glutamine deprivation. 
 
Results 
To measure the sensitivity of prostate cancer cells to glutamine deprivation, we 
evaluated the MTT staining (which measures cell metabolic activity and reflects in part 
the number of viable cells), number, proliferation, cell cycle, apoptosis and autophagy 
of PC3 and LNCaP cell lines cultured under different concentrations of glutamine for 72 
hours. MTT staining of both cell lines was gradually reduced with decreasing 
glutamine, showing an approximately 40% decrease in the complete absence of 
glutamine (p<0.05) (Figure 1A-B). Glucose deprivation in the presence of normal 
glutamine concentration (300 mg/L) also decreased MTT staining (Figure 1C-D), 
indicating that glutamine is necessary though insufficient to maintain high cellular 
metabolic rates. PC3 and LNCaP cell number and relative proliferation decreased when 
cultured under an intermediate concentration (37.5 mg/mL) or absence of glutamine 
(Figure 1E-H). PC3 cell cycle is not statistically changed by the reduction or absence of 
glutamine (Figure 1I). In LNCaP cells, glutamine reduction induced an accumulation in 
S and G2/M cell cycle phases, whereas the complete absence of glutamine decreased the 
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percentage of cells in G2/M phases (Figure 1J). Surprisingly, a significant protective 
effect on apoptosis was observed by reduction or absence of glutamine in LNCaP cells 
but not PC3 cells (Figure 1K-L). Autophagy was not induced by glutamine reduction in 
either PC3 or LNCaP cells, as indicated by the ratio of LC3II/I (Figure M-N).  
We next sought to investigate the activities of RhoA and RhoC in prostate 
cancer cells cultured under glutamine deprivation. PC3 cells cultured under reduction or 
absence of glutamine showed a trend of increase in RhoA and RhoC activities, 
compared to normal glutamine concentration (Figure 2A-B). In LNCaP cells, RhoA and 
RhoC activity showed a trend of a biphasic response to glutamine levels: it was 
increased at the intermediate dose and slightly reduced in the absence of glutamine 
when compared to normal glutamine concentration (Figure 2C-D).  
We then investigated the effects of RhoA and RhoC on glutamine dependency 
by stably expressing GFP-tagged wild type and dominant negative mutants of RhoA 
(RhoA
N19
) and RhoC (RhoC
N19
) in PC3 cells. Transfection efficiency was confirmed by 
GFP detection using flow cytometry (Figure 3A) and western blotting (Figure 3B-C).  
More than 60% of GFP positive cells were obtained in all conditions, with the exception 
of RhoC
wt
 expression, which resulted in a strong reduction in cell proliferation and 
consequent low transfection efficiency with approximately 10% of GFP-positive cells 
after sorting (Figure 3A). Cell morphology was visualized by fluorescence microscopy 
to detect GFP (Figure 3D) and cell area and circularity were analyzed. RhoA
wt
 [median 
405 (range 134 – 1757 µm
2
)], RhoA
N19
 [788 (164 – 1907 µm
2
)], RhoC
wt
 [930 (291 – 1652 
µm
2
)] and RhoC
N19 
[547 (198 – 2104 µm
2
)] expressing cells had decreased cell area in 
comparison with control cells (empty vector) [1072 (269 – 3365 µm
2
)], all P<0.05 
(Figure 3E). Circularity was decreased in RhoA
N19
 [median 0.36 (range 0.06 – 0.94)] and 
increased in RhoC
N19
 [0.72 (0.32 – 0.93)] expressing cells, compared to control [0.52 
(0.12 – 0.84)], all P<0.05 (Figure 3F); ANOVA with Dunnett´s post-test. It was not 
possible to study the responses of RhoC
wt
-expressing cells to glutamine deprivation due 
to the low transfection efficiency (data not shown). Expression of RhoA
wt
 and RhoA
N19
 
decreased MTT cell labelling under normal glutamine concentration (300 mg/L). PC3 
cells expressing RhoA
wt
 were still sensitive to glutamine deprivation (Figure 3G). 
Conversely, PC3 cells expressing RhoA
N19
 or RhoC
N19
 were more resistant to glutamine 
deprivation, since their MTT labelling was not significantly affected by glutamine 
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withdrawal (Figure 3G-H). Apoptosis was not significantly altered by RhoA
wt
, RhoA
N19
 
or RhoC
N19 
in any of the tested conditions (Figure 3I-J). 
 
Discussion 
Reliance on glutamine varies substantially between different cancer cells. Some types of 
cells are highly sensitive to glutamine deprivation, while others do not require an 
exogenous source of this amino acid to survive 
4
. Here we show that PC3 and LNCaP 
prostate cancer cells respond to glutamine reduction or deprivation mainly by decreased 
cell proliferation. However, the effects of glutamine deprivation on the cell cycle and 
apoptosis varied between these cell lines. PC3 and LNCaP cells were established from 
very different prostate tumors 
11, 12
 and diverge in their metastatic potential, gene 
expression profile and metabolism control
13, 14
. Therefore, our data are in accordance 
with other studies that showed that glutamine sensitivity is related to aggressiveness 
15
, 
modulation of glucose metabolism and the status of other genes 
16
.  
It is interesting that PC3 cells and LNCaP cells show different patterns of 
RhoA/RhoC activity depending on glutamine levels. Whereas both RhoA and RhoC 
activity increased in PC3 cells in response to glutamine reduction or deprivation, in 
LNCaP cells, RhoA and RhoC activity was increased only under glutamine reduction 
but not deprivation. Rho GTPases play a part in G1 progression in many cell types 
17
 
and the biphasic response in RhoA/RhoC activity is similar to the decrease in G1 cell 
cycle phase in LNCaP cells cultured in reduced glutamine levels. Thus, it is possible 
that increased RhoA/RhoC activity stimulates G1/S phase transition in these cells. In 
addition, our previous study showed that PC3 cells are more responsive to the alteration 
of RhoA and RhoC pathways compared to LNCaP cells 
18
, which may also explain the 
difference induced by glutamine deprivation in RhoA/C activities between the cell lines. 
 Stable overexpression of wild type or dominant negative mutants of RhoA or 
RhoC produced substantial alterations in the morphology and MTT staining of PC3 
cells even in normal glutamine concentration. Cell circularity was increased by RhoA
N19 
and decreased by RhoC
N19
, highlighting the different functions of these two highly 
homologous proteins. Distinct effects of RhoA and RhoC have been previously 
described in the morphology of prostate cancer cells 
9, 19
. In addition, RhoC
wt
 effects on 
the reduction of MTT staining were stronger than RhoA
wt
. RhoA or RhoC have been 
described to increase cell growth 
18, 20, 21
. However, their stable overexpression may also 
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lead to a decrease in cell growth caused by the profound changes in the cytoskeleton 
22, 
23
, which is accordance with our results.  
RhoA and RhoC can have both pro- and anti-oncogenic activities depending on 
the context 
24-26
. In addition, RhoA gain and loss-of-function mutations have been 
identified in cancer patients 
27, 28
. We observed that dominant negative mutant forms of 
RhoA or RhoC prevented the decrease in MTT staining induced by glutamine 
deprivation, implying that RhoA and RhoC promote growth inhibition under these 
conditions. Inflammatory breast cancer cells depleted for RhoC presented decreased 
glutamine uptake, but remained dependent on glutamine 
6
. However, this is the first 
time that RhoA
N19
 and RhoC
N19
 effects on glutamine sensitivity are evaluated. All 
together, these results indicate that determining RhoA/C activity in cancer cells is 
relevant when considering targeting the glutamine pathway therapeutically.  
Further studies are important to elucidate the roles of RhoA and RhoC in 
glutamine metabolism. Our findings add new insights regarding the participation of 
these two proteins in the sensitivity of prostate cancer cells to glutamine deprivation. 
 
Materials and Methods 
Cell culture 
The human prostate cancer cell lines LNCaP and PC3 were acquired from ATCC 
(American Type Culture Collection, Philadelphia, USA). Cells were cultured in RPMI 
medium (Gibco) with 10% FBS and maintained in a humidified incubator at 37°C and 
5% CO2. To evaluate the cellular response to glutamine deprivation, cells were grown in 
culture medium containing 10% FBS and different glutamine concentrations.  
 
MTT assays and determining cell number 
For Methylthiazoletetrazolium (MTT; 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide) (Sigma) staining, 9×10
3 
cells per well were cultured in 96-well 
plates in RPMI with 10% FBS for 72 hours. After this period, 10 µL of 5 mg/mL MTT 
solution were added to each well and the cells were incubated at 37°C for 4 hours. The 
reaction was stopped by addition of 100 µl of 0.1 N HCl in isopropanol and the optical 
densities were measured with a spectrophotometer at 595 nm absorbance. Cell number 
was calculated by counting the cells cultured under different conditions using a 
Neubauer chamber. 
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CFSE cell labelling  
Cell proliferation was evaluated by CellTrace™ CFSE Cell Proliferation Kit Protocol 
(Thermofisher) according manufacture instructions. In brief, 2×10
5
 cells were staining 
with 5 μM carboxyfluorescein diacetate, succinimidyl ester (CFSE) for 20 minutes in a 
37°C water bath, washed and returned cell culture in the presence or absence glutamine. 
After 0 (initial time) and 72 (proliferation time) hours, CFSE fluorescence intensity 
analyzed in a FACSCalibur (BD Biosciences). The proliferation indexes were 
determined using the ModFit Software (BD Biosciences). Ten thousand events were 
acquired for each sample. 
 
Cell cycle analysis 
Cell cycle was evaluated by flow cytometry, as previously described 
29
. Briefly, the 
cells were collected, fixed in 70% ethanol and stored at 4°C for at least 4 hours. After 
washing in PBS, the samples were suspended in cell cycle buffer (0.1% Triton X-100, 
10 mg/mL propidium iodide, 0.1 mg/mL RNase A) and incubated at 37°C for 30 
minutes. Fluorescence was detected with a FACSCalibur (BD Biosciences) and ModFit 
Software (BD Biosciences) was used to determine the proportions of cells in each cell 
cycle phase. Ten thousand events were acquired for each sample. 
 
Rho GTPase activity assays 
RhoA, Cdc42 and RhoC activities were determined by affinity precipitation assay, as 
previously described 
18
.  Briefly, cell lysates (25mM Hepes, pH 7.5, 150mM NaCl, 1% 
Nonidet P-40, 10mM MgCl2, 1mM EDTA, 25mM NaF, 1mM Na3VaO4, 10μg/mL 
aprotinin, 100μM PMSF, and 10% glycerol) were incubated with the GST-RBD at 4°C 
with rotation for 4 hours. After four washes, the pull down samples and total protein 
extracts were subjected to SDS-PAGE and western blotting analysis with specific 
antibodies. 
 
Western blotting 
Cells were lysed with protein extraction buffer containing 100 mM Tris (pH 7.6), 1% 
Triton X-100, 150 mM NaCl, 0.1 mg Aprotinin, PMSF, 35 mg/mL, 10 mM Na3VO4, 
100 mM NaF, 10 mM Na4P2O7 and 4 mM EDTA. The protein extracts were subjected 
to SDS-PAGE and western blotting analysis with specific primary antibodies: anti-LC3 
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(ab128025) from abcam, Anti-RhoA (2117S) and anti-RhoC (3430S) from Cell 
Signaling Technology and anti-GFP (sc-9996) from Santa Cruz Technologies. The 
ECLTM Western Blotting Analysis System kit (Amersham Pharmacia Biotech) was 
used for developing. Anti-actin (sc-1616) or anti-GAPDH (sc-32233) from Santa Cruz 
Biotechnology were used as loading control and band quantification was performed 
with UN-SCAN-IT gel densitometry software. 
 
Stable transfection 
GFP-fusions of wild type forms of RhoA (RhoA
wt
) and RhoC (RhoC
wt
) and dominant 
negative mutants of RhoA (RhoA
N19
) and RhoC (RhoC
N19
) (in EGFP) were transfected 
into PC3 cells. Briefly, the cells were transfected using jetPEI (Polyplus transfection), 
according to the manufacturer´s instructions. Cells expressing eGFP were used as 
control cells. Cells were then selected with 700µg/mL G418 (geneticin) for at least ten 
days then sorted for GFP using a FACsAria Fusion (Becton–Dickinson Biosciences).  
 
Analysis of cellular morphology 
Cell morphology was observed by fluorescence microscope through GFP detection. 
Image J software (National Institutes of Health) was used to measure the cell area and 
circularity. Circularity was calculated as previously described 
30
 and values ranged from 
0.0 to 1.0, where a value of 1.0 designates a perfect circular shape and a value of 0.0 
indicates an elongated polygon. At least 30 cells were analyzed for each condition.  
 
Assessment of apoptosis  
Apoptosis was determined with Annexin V Apoptosis Detection Kit (BD Biosciences), 
according to the manufacturer’s instructions. All specimens were analyzed by a 
FACSCalibur (BD Biosciences) and at least ten thousand events were acquired for each 
sample. 
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., 
San Diego, CA, USA). For comparisons, ANOVA test and Dunnett´s post-test were 
used. A P value <0.05 was considered as statistically significant. 
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Figure Legends 
Figure 1. Effects of glutamine reduction on prostate cancer cell MTT staining, cell 
number, CFSE cell labelling, cell cycle, apoptosis and autophagy. PC3 and LNCaP 
cells were cultured for 72 hours under the indicated glutamine concentrations. (A-B) 
PC3 and LNCaP cell growth are decreased by reduced glutamine in the presence of 
glucose and (C-D) by reduced glucose in the presence of glutamine. (E-H) Decreased 
LNCaP and PC3 cell number and proliferation under reduced glutamine conditions. (I) 
PC3 cell cycle is not statistically changed by the reduction or absence of glutamine. (J) 
In LNCaP cells, reduced glutamine induces an accumulation in the S and G2-M phases 
of the cell cycle, whereas the absence of glutamine leads to the reduction of G2/M 
phases of the cell cycle. (K-L) The percentage of annexin V-positive cells was 
decreased upon glutamine reduction in LNCaP cells, but not in PC3 cells.  (M-N) 
Glutamine reduction did not alter the ratio of LC-3II/LC3I in PC3 and LNCaP cells. 
Actin (42 kDa) was used to determine sample loading; the antibodies used for 
immunoblotting (IB) are indicated. Densitometry was performed and the ratio of target 
protein versus actin compared with the normalized value of control is shown. Analysis 
of variance (ANOVA) followed by a Dunnett´s test was used to determine significance. 
*P<0.05, **P<0.01, ***P<0.01. NS = not significant. Data shown are presented as 
mean ± standard deviation from at least four independent experiments. 
 
Figure 2. Effects of glutamine reduction on the activities of RhoA and RhoC in 
PC3 and LNCaP cells. (A-B) RhoA and RhoC activities trend to increase by glutamine 
reduction or deprivation in PC3 cells. (C-D) LNCaP cells cultured under the 
intermediate glutamine concentration (37.5 mg/L) presented a trend of increase in RhoA 
and RhoC activities, whereas a trend of decrease in RhoA and RhoC activities was 
observed upon glutamine deprivation. (Upper panel) RhoA and RhoC activities were 
determined by pool down assays; actin (42 kDa) or GAPDH (37 kDa) were used to 
determine sample loading; the antibodies used for immunoblotting (IB) are indicated. 
(Lower panel) Bar graphs represent relative densitometry ratios of RhoA-GTP/RhoA 
(total) and RhoC-GTP/RhoC (total) of at least three independent experiments.  
 
Figure 3. Effects of the overexpression of wild type and dominant negative mutant 
RhoA/C in PC3 and LNCaP cells cultured under graded reduction of glutamine. 
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(A) PC3 cells were stably transfected with wild type (RhoA
wt
 or RhoC
wt
) and dominant 
negative mutant RhoA/C (RhoA
N19
 or RhoC
N19
) fused to green fluorescent protein 
(GFP) and transfection efficiency was evaluated by flow cytometry. PC3 cells 
expressing eGFP were used as a control. (B-C) Transfection efficiency was also 
assessed by western blotting using anti-RhoA, anti-RhoC (upper blots) and anti-GFP 
antibodies (middle blots). Actin (42 kDa) or GAPDH (36 kDa) were used to determine 
sample loading. (D) Morphology of PC3 cells expressing RhoA
wt
, RhoC
wt
, RhoA
N19
 and 
RhoC
N19
 was observed by fluorescence microscopy through GFP detection. Scale bar = 
50µm. (E-F) Area and circularity of PC3 cells were quantified with Image J Software. 
ANOVA followed by a Dunnett´s test was used to determine significance. *P<0.05, 
***P<0.01. (G-H) Relative MTT staining of PC3 cells expressing RhoA
wt
, RhoA
N19
 and 
RhoC
N19
. Expression of RhoA
wt
 and RhoA
N19
 decreased MTT staining under normal 
glutamine concentration (300mg/L) (both ***P≤0.001). Glutamine deprivation 
decreases the MTT staining in control cells (empty vector) and in RhoA
wt
 expressing 
cells (
###
P≤0.001), but not in RhoAN19 or RhoCN19 expressing cells (NS=not significant). 
(I-J) Expression of RhoA
wt
, RhoA
N19
 and RhoC
N19
 did not alter the apoptosis of PC3 
cells cultured in the presence or absence of glutamine. ANOVA followed by a 
Bonferroni test was used to determine significance.  
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